STOCK TITAN

Kronos Bio, Inc. - $KRON STOCK NEWS

Welcome to our dedicated page for Kronos Bio news (Ticker: $KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kronos Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kronos Bio's position in the market.

Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) reported positive preliminary data from the Phase 1 dose escalation portion of the KB-0742 study at AACR-NCI-EORTC and CTOS conferences. This data showed on-mechanism, single agent anti-tumor activity and a manageable safety profile in pre-treated patients with transcriptionally addicted solid tumors. The company also announced a plan to optimize resource allocation, restructure, and contain costs, extending its cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
-
Rhea-AI Summary
Kronos Bio, Inc. announces a plan to optimize resource allocation and restructure in light of positive clinical data from its Phase 1/2 study of KB-0742. The company will focus on exploring KB-0742's potential, advancing lanraplenib development, and maturing projects. Restructuring efforts include a 19% reduction in force and are expected to extend the company's cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
-
Rhea-AI Summary
Kronos Bio, Inc. presented positive preliminary data from the phase 1 dose escalation portion of the ongoing KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data showed on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors. Preclinical studies also demonstrated KB-0742's activity in models for rhabdomyosarcoma and Ewing sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
Rhea-AI Summary
Kronos Bio, Inc. will present positive preliminary data from the ongoing KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data includes clinical data presented at a previous conference and provides a better understanding of the observed anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
conferences clinical trial
-
Rhea-AI Summary
Kronos Bio announces positive preliminary data from Phase 1 trial of KB-0742 for treating transcriptionally addicted solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.65%
Tags
-
Rhea-AI Summary
Kronos Bio to host conference call and webcast on October 13 to discuss KB-0742 trial for MYC-dependent solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.38%
Tags
conferences clinical trial
Rhea-AI Summary
Kronos Bio's Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, will resign to become CEO of a private biotech company. The company will search for a replacement, and Al-Wakeel will stay until September 15 for a smooth transition. Al-Wakeel's contributions include leading a successful IPO and establishing partnerships for continued success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
conferences
Kronos Bio, Inc.

Nasdaq:KRON

KRON Rankings

KRON Stock Data

63.10M
43.75M
19.59%
44.68%
1.11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN MATEO

About KRON

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.